CN100389779C - Medicine composition used for cleaning intestinal tract - Google Patents
Medicine composition used for cleaning intestinal tract Download PDFInfo
- Publication number
- CN100389779C CN100389779C CNB2006100986069A CN200610098606A CN100389779C CN 100389779 C CN100389779 C CN 100389779C CN B2006100986069 A CNB2006100986069 A CN B2006100986069A CN 200610098606 A CN200610098606 A CN 200610098606A CN 100389779 C CN100389779 C CN 100389779C
- Authority
- CN
- China
- Prior art keywords
- bubble
- intestinal
- examples
- polyethylene glycol
- organizes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a medicine composition used for cleaning the intestinal tract and composed of polyethylene glycol 4000, sodium bicarbonate, sodium chloride, potassium chloride and dimeticone, which belongs to the field of biologic medicine.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that is used for intestinal tract cleaning, belong to biomedicine field.
Background technology
Doing colonoscopy to the patient, and the intestinal of lumbar vertebra film making, intestinal inspection, abdominal operation all need carry out intestinal tract cleaning earlier when preparing, intestinal tract cleaning prepare to check and the success or not of treatment work extremely important.
Polyethylene glycol electrolyte liquid has been widely used in intestinal tract cleaning at home and abroad in recent years, as a kind of impermeability, nonabsorbable, unexplosive WBI liquid, safe and effective, fast and convenient, easily accepted by the patient, but we find such problem in application process: when the application polyethylene glycol electrolyte carries out intestinal tract cleaning, have bubble to produce under endoscopic views, influence is checked and treatment.
At the problems referred to above, we have carried out detailed research, have finished the present invention, and the bubble of a kind of effective elimination polyethylene glycol electrolyte liquid in that enteral produces is provided, and can give full play to the compositions of the good enteron-cleaning effect of polyethylene glycol electrolyte liquid again.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition with enteron-cleaning effect.
For achieving the above object, the present invention is by the following technical solutions:
Pharmaceutical composition with enteron-cleaning effect, wherein unit dose contains Macrogol 4000 105g, 1.428g sodium bicarbonate, 2.8056g sodium chloride, 0.3728g potassium chloride, simethicone 0.24～1.2g.
The invention has the beneficial effects as follows and when guaranteeing the intestinal tract cleaning effect, reduce the bubble that polyethylene glycol electrolyte solution produces, thereby improve the beneficial effect of treatment under microscopy and the mirror.
The specific embodiment
Embodiment 1:
Physical data:
The patient (except intestinal obstruction, acute gastrointestinal bleeding and acute abdomen) that 200 examples are accepted colonoscopy is divided into 2 groups (A, B) at random, A organizes oral polyethylene glycol electrolyte powder (Shutaishen (Beijing) Pharmaceutical Co., Ltd. provides), B organizes the compositions of oral polyethylene glycol electrolyte powder and simethicone, and wherein the unit dose of simethicone is 0.24g (our company's laboratory provides).Have 198 routine patients and finish research, wherein A organizes 98 examples (wherein male 42 examples, women 56 examples), 45.3 years old mean age; B organizes 100 examples, (wherein male 66 examples, women 34 examples), 47.5 years old mean age.Except that sex, three groups are not being had significant difference aspect age, height, the body weight.
Polyethylene glycol electrolyte solution 4L was taken in the colonoscopy of A group in preceding 4 hours, took medicine by the speed of about 1L per hour, and discharged liquid is bordering on carries out colonoscopy when transparent.
The preceding composition solution 4L (dosage of simethicone is 0.48g) that took polyethylene glycol electrolyte powder and simethicone in 4 hours of B group colonoscopy takes medicine by the speed of about 1L per hour, and discharged liquid is bordering on carries out colonoscopy when transparent.
Observation index:
There is the bubble situation in observation: 1. almost can't see bubble in the intestinal tube; 2. the interior bubble of intestinal tube seldom; 3. bubble is a lot of in the intestinal tube.
There is situation according to the colonic bubble, estimates the intestinal defoaming effect; 1. significantly effectively: almost can't see bubble in the intestinal tube, can observe well; 2. effective: as only to exist in the intestinal tube and seldom measure bubble, do not have influence to observing; 3. invalid: as a lot of bubbles to be arranged in the intestinal tube, can't observe.Total effective rate=(significantly effectively+effectively)/total case load * 100%.
There is situation in bubble in the intestinal:
A organizes 82 routine produce effects, and obvious effective rate is that 83.67%, 16 example is effective, and total effective rate is 100%; B organizes 94 routine produce effects, and obvious effective rate is 94.00%, effective 6 examples, and total effective rate is 100%, two group and relatively there are differences.
Embodiment 2:
Physical data:
The patient (except intestinal obstruction, acute gastrointestinal bleeding and acute abdomen) that 220 examples are accepted colonoscopy is divided into 2 groups (A, B) at random, A organizes oral polyethylene glycol electrolyte powder (Shutaishen (Beijing) Pharmaceutical Co., Ltd. provides), B organizes the compositions of oral polyethylene glycol electrolyte powder and simethicone, and wherein the unit dose of simethicone is 1.2g (our company's laboratory provides).Have 218 routine patients and finish research, wherein A organizes 118 examples (wherein male 62 examples, women 56 examples), 46.6 years old mean age; B organizes 100 examples, (wherein male 56 examples, women 44 examples), 48.2 years old mean age.Except that sex, three groups are not being had significant difference aspect age, height, the body weight.
Polyethylene glycol electrolyte solution 4L was taken in the colonoscopy of A group in preceding 4 hours, took medicine by the speed of about 1L per hour, and discharged liquid is bordering on carries out colonoscopy when transparent.
The preceding composition solution 4L (dosage of simethicone is 2.4g) that took polyethylene glycol electrolyte powder and simethicone in 4 hours of B group colonoscopy takes medicine by the speed of about 1L per hour, and discharged liquid is bordering on carries out colonoscopy when transparent.
Observation index:
There is the bubble situation in observation: 1. almost can't see bubble in the intestinal tube; 2. the interior bubble of intestinal tube seldom; 3. bubble is a lot of in the intestinal tube.
There is situation according to the colonic bubble, estimates the intestinal defoaming effect; 1. significantly effectively: almost can't see bubble in the intestinal tube, can observe well; 2. effective: as only to exist in the intestinal tube and seldom measure bubble, do not have influence to observing; 3. invalid: as a lot of bubbles to be arranged in the intestinal tube, can't observe.Total effective rate=(significantly effectively+effectively)/total case load * 100%.
There is situation in bubble in the intestinal:
A organizes 99 routine produce effects, and obvious effective rate is that 83.90%, 19 example is effective, and total effective rate is 100%; B organizes 99 routine produce effects, and obvious effective rate is 99.00%, effective 1 example, and total effective rate is 100%, two group and relatively there are differences.
Observing the B group in this test has 2 routine patients extremely slight erythra to occur, suspects relevant with the dosage that increases simethicone.
Embodiment 3:
Physical data:
The patient (except intestinal obstruction, acute gastrointestinal bleeding and acute abdomen) that 210 examples are accepted colonoscopy is divided into 2 groups (A, B) at random, A organizes oral polyethylene glycol electrolyte powder (Shutaishen (Beijing) Pharmaceutical Co., Ltd. provides), B organizes the compositions of oral polyethylene glycol electrolyte powder and simethicone, and wherein the unit dose of simethicone is 0.80g (our company's laboratory provides).Have 210 routine patients and finish research, wherein A organizes 100 examples (wherein male 44 examples, women 56 examples), 47.9 years old mean age; B organizes 110 examples, (wherein male 56 examples, women 54 examples), 49.1 years old mean age.Except that sex, three groups are not being had significant difference aspect age, height, the body weight.
Polyethylene glycol electrolyte solution 4L was taken in the colonoscopy of A group in preceding 4 hours, took medicine by the speed of about 1L per hour, and discharged liquid is bordering on carries out colonoscopy when transparent.
Polyethylene glycol electrolyte powder and the diffusing composition solution 4L (dosage of simethicone is 1.6g) of simethicone were taken in the colonoscopy of B group in preceding 4 hours, took medicine by the speed of about 1L per hour, and discharged liquid is bordering on carries out colonoscopy when transparent.
Observation index:
There is the bubble situation in observation: 1. almost can't see bubble in the intestinal tube; 2. the interior bubble of intestinal tube seldom; 3. bubble is a lot of in the intestinal tube.
There is situation according to the colonic bubble, estimates the intestinal defoaming effect; 1. significantly effectively: almost can't see bubble in the intestinal tube, can observe well; 2. effective: as only to exist in the intestinal tube and seldom measure bubble, do not have influence to observing; 3. invalid: as a lot of bubbles to be arranged in the intestinal tube, can't observe.Total effective rate=(significantly effectively+effectively)/total case load * 100%.
There is situation in bubble in the intestinal:
A organizes 84 routine produce effects, and obvious effective rate is that 84.00%, 16 example is effective, and total effective rate is 100%; B organizes 108 routine produce effects, and obvious effective rate is 98.18%, effective 2 examples, and total effective rate is 100%, two group and relatively there are differences.
Claims (1)
1. pharmaceutical composition that is used for intestinal tract cleaning, its unit dose contains the 105g Macrogol 4000, the simethicone of 1.428g sodium bicarbonate, 2.8056g sodium chloride, 0.3728g potassium chloride and 0.24～1.20g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100986069A CN100389779C (en) | 2006-07-07 | 2006-07-07 | Medicine composition used for cleaning intestinal tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100986069A CN100389779C (en) | 2006-07-07 | 2006-07-07 | Medicine composition used for cleaning intestinal tract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1868486A CN1868486A (en) | 2006-11-29 |
| CN100389779C true CN100389779C (en) | 2008-05-28 |
Family
ID=37442352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100986069A Active CN100389779C (en) | 2006-07-07 | 2006-07-07 | Medicine composition used for cleaning intestinal tract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100389779C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766648B (en) * | 2010-03-02 | 2012-01-11 | 舒泰神（北京）生物制药股份有限公司 | Polyethylene glycol electrolyte granular preparation and production method |
| KR101423005B1 (en) | 2013-10-17 | 2014-07-28 | 강윤식 | Bowel Cleansing Composition |
| CN112870382B (en) * | 2021-01-28 | 2023-05-26 | 复旦大学附属中山医院 | Combination of arabinose and silicone oil defoamer for intestinal tract preparation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150021A (en) * | 1996-01-11 | 1997-05-21 | 李智军 | Bowel clearing agent |
| CN1288730A (en) * | 1999-09-07 | 2001-03-28 | 麦克内尔-Ppc股份有限公司 | Slight-purgitive composition |
| JP2003073260A (en) * | 2001-08-30 | 2003-03-12 | Nihon Pharmaceutical Co Ltd | Composition for oral enterolavage liquid and packed preparation for the oral enterolavage liquid |
| WO2005097144A1 (en) * | 2004-04-02 | 2005-10-20 | Ajinomoto Co., Inc. | Composition for cleaning intestinal canal |
| CN1705494A (en) * | 2002-10-25 | 2005-12-07 | 诺金欧洲公司 | Colon cleansing compositions and methods |
-
2006
- 2006-07-07 CN CNB2006100986069A patent/CN100389779C/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150021A (en) * | 1996-01-11 | 1997-05-21 | 李智军 | Bowel clearing agent |
| CN1288730A (en) * | 1999-09-07 | 2001-03-28 | 麦克内尔-Ppc股份有限公司 | Slight-purgitive composition |
| JP2003073260A (en) * | 2001-08-30 | 2003-03-12 | Nihon Pharmaceutical Co Ltd | Composition for oral enterolavage liquid and packed preparation for the oral enterolavage liquid |
| CN1705494A (en) * | 2002-10-25 | 2005-12-07 | 诺金欧洲公司 | Colon cleansing compositions and methods |
| WO2005097144A1 (en) * | 2004-04-02 | 2005-10-20 | Ajinomoto Co., Inc. | Composition for cleaning intestinal canal |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1868486A (en) | 2006-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2584866T3 (en) | Purgative composition for the colon with soluble binding agent | |
| CN104163876B (en) | Chitosan quaternary ammonium product salt and preparation method thereof | |
| CN101389343B (en) | Doxorubicin formulations for anti-cancer use | |
| CN100389779C (en) | Medicine composition used for cleaning intestinal tract | |
| CN108366975A (en) | Treatment using deoxycholic acid and its salt to the fat of accumulation | |
| CN102836171B (en) | Solution for surgery and endoscope washing and preparation method thereof | |
| CN105919926B (en) | A kind of Carbomer cervical gel and preparation method thereof | |
| CN1149255A (en) | Use of magnesium-based products for the treatment or prophylaxis of neoplastic and autoimmune diseases | |
| WO2021253008A1 (en) | Partially desulfated heparin for treating coronaviral infections | |
| TW201105340A (en) | Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease | |
| CN107854693A (en) | The anticancer conjugate of integrin receptor target | |
| CN102526005A (en) | Application of deferoxamine mesylate in preparing medicaments for treating postmenopausal osteoporosis | |
| CN103142461B (en) | A kind of vaginal gel and preparation method thereof | |
| Katz et al. | Nocardia asteroides sinusitis: Presentation as a trimethoprim-sulfamethoxazole responsive fever of unknown origin | |
| CN102579419B (en) | Novel anticancer application of chlorogenic acid | |
| Feo et al. | Retroperitoneal abscess and omphalitis in young infants | |
| CN102973940A (en) | Pharmaceutical composition for inhibiting or killing helicobacter pylori and use thereof | |
| CN102295683B (en) | Anti-herpes simplex virus polypeptide and its application | |
| CN103948614B (en) | The pharmaceutical applications of otoginsenoside and salt thereof | |
| Laktašić-Žerjavić et al. | Septic acromioclavicular arthritis in a patient with diabetes mellitus | |
| CN101461807A (en) | Application of penehyclidine hydrochloride in preparing medicament for treating haemorrhagic shock | |
| CN104147184B (en) | Medicine for nursing of postpartum urinary retention | |
| Bi-qiong et al. | A clinical study on the treatment of chronic pelvic inflammation of Qi-stagnation with blood stasis syndrome by Penyanqing capsule | |
| KR101842041B1 (en) | Purgative composition | |
| CN101966334A (en) | Application of lecithin superoxide dismutase composite in preparation of medicines for treating and/or preventing cardiac ischemic injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: BEIJING STAIDSON NEW MEDICINE RESEARCH CO., LTD. Free format text: FORMER NAME: BEIJING ZHAOYAN BONA NEW MEDICINE RESEARCH CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 100176, 5A203, room 5, wing Jingdong street, Beijing economic and Technological Development Zone, Beijing, China Patentee after: BEIJING STAIDSON NEW DRUG RESEARCH CO., LTD. Address before: 100176, 5, Jingdong street, Beijing economic and Technological Development Zone Patentee before: Beijing Zhaoyan Bona New Medicine Research Co., Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 100176, Beijing economic and Technological Development Zone, Beijing, No. two, No. 36, No. 5, No. 501, room Patentee after: Beijing Choutet doctor medicine technology Ltd Address before: 100176, 5A203, room 5, wing Jingdong street, Beijing economic and Technological Development Zone, Beijing, China Patentee before: BEIJING STAIDSON NEW DRUG RESEARCH CO., LTD. |
|
| CP03 | Change of name, title or address |